NPPB and chronic kidney disease: The post hoc analysis of the EVEREST clinical trial, in 3,500 patients, showed that markers of aggressive decongestion that improved when treated with diuretics in ADHF, such as decreased values of BNP, NT-proBNP, congestion scores or increments of hematocrit, albumin and total proteins are associated with lower probabilities of being diagnosed with CKD grade 4 after a long follow-up of 10 months, reducing this risk by 70% (54).